Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective
This Danish study aimed to assess the impact of age and comorbidities on PFS and OS for patients with ER-positive, HER2 normal, advanced breast cancer treated with palbociclib and AI. In this MEDtalk, Alan Celik, MD, Danish Breast Cancer Group (DBCG), presents the results from the study.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
